- Details
- Charles Ryan presented the management of fatigue and cognitive changes induced by androgen deprivation therapy (ADT) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Ryan discusses the association between ADT and dementia, and also how combining ADT with abiraterone and prednisone can significantly improve fatigue in patients. Biographies: Charles J. Ryan, MD , the President...
|
- Details
- Neal Shore presents on the metabolic complications of androgen deprivation therapy and how to manage them at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Biography: Neal Shore, MD , Medical Director for the Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA. Related Content: APCCC 2019: Management of Metabolic Changes Download Presentation Slides Read the Full...
|
- Details
- Karim Fizazi presented on global access to treatment of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He includes data on current access to radiotherapy on a worldwide level, the use of generic drugs, including docetaxel, abiraterone, and cabazitaxel expected to start in 2021. Lastly, he highlights the use of surgical castration vs. the use of LHRH ago...
|
- Details
- Mark Rubin presents on the future of metastatic prostate cancer in regards to biomarkers at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He discusses both predictive and prognostic biomarkers, currently used biomarker tests, and a summary of some of the many studied biomarkers that are ready and appear promising. In conclusion he shares his beliefs of what we now require which a...
|
- Details
- In the last 10 years, there has been tremendous progress in the available treatment options for metastatic prostate cancer patients. In this presentation from William Oh at the 2019 Advanced Prostate Cancer Consensus Conference he highlights available treatment options for metastatic prostate cancer patients including serial systemic therapy with combinations of ADT with chemotherapy, abiraterone,...
|
- Details
- Eleni Efstathiou presents an overview of neuroendocrine prostate cancer during the Management of Castration-Resistant Prostate Cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Efstathiou touches on the inaccuracies in the terminology of neuroendocrine prostate cancer, the current state of aggressive variant prostate cancer, where efforts are in place to...
|
- Details
- Christopher Sweeney presents on systemic therapy for prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). The spectrum of patients starting androgen deprivation therapy (ADT) for metastatic disease is quite vast. Discussing several treatments and several studies as well as their overall survival treatment benefit Dr. Sweeney focuses on which systemic therapy for which...
|
- Details
- William Oh highlights the first study of people who were exposed to the World Trade Center dust and who subsequently developed prostate cancer. World Trade Center responders with prostate cancer showed signs that inflammation was activated in the prostate after exposure to dust from the World Trade Center site, possibly causing chronic inflammation that contributed to their cancer, according to a...
|
- Details
- During the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) Himisha Beltran presented an overview looking into the future of oligometastatic disease, and where she predicts we will be in two years’ time. Her presentation focused on refined clinical definitions for disease stratification, nominated molecular biomarkers to capture biologic disease states and defined goals of care for impro...
|
- Details
- Alicia Morgans and Ian Davis presented an update on the IRONMAN study, an International Registry for Men with Advanced Prostate Cancer at the Advanced Prostate Cancer Consensus Conference (APCCC). The ultimate goal of this project is to provide the most elaborate description and understanding of patients with advanced prostate cancer. The project includes a description of treatment changes, advers...
|
